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We have previously observed that all known potent broadly neutralizing antibodies (bnAbs)
against HIV-1 are highly divergent from their putative germline predecessors in contrast to
bnAbs against viruses causing acute infections such as henipaviruses and SARS CoV, which
are much less divergent from their germline counterparts. Consequently, we have hypoth-
esized that germline antibodies may not bind to the HIV-1 envelope glycoprotein (Env)
because they are so different compared to the highly somatically mutated HIV-1-specific
bnAbs. We have further hypothesized that the immunogenicity of highly conserved epi-
topes on the HIV-1 envelope glycoproteins (Envs) may be reduced or eliminated by their
very weak or absent interactions with germline antibodies and immune responses leading
to the elicitation of bnAbs may not be initiated and/or sustained. Even if such responses are
initiated, the maturation pathways are so extraordinarily complex that prolonged periods
of time may be required for elicitation of bnAbs with defined unique sequences. We pro-
vided the initial evidence supporting this antibody germline/maturation hypothesis, which
prompted a number of studies to design vaccine immunogens that could bind putative
germline predecessors of known bnAbs and to explore complex B cell lineages. However,
guiding the immune system through the exceptionally complex antibody maturation path-
ways to elicit known bnAbs remains a major challenge. Here, we discuss studies exploring
the antibody germline/maturation hypothesis as related to elicitation of bnAbs against HIV-
1 and present our recent data demonstrating the existence of germline-like precursors of
VRC01 antibodies in a human cord blood IgM library.
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INTRODUCTION
Elicitation of broadly neutralizing antibodies (bnAbs) targeting
the HIV-1 envelope glycoproteins (Envs), the key to an effective
HIV-1 vaccine, remains elusive. Previous studies have demon-
strated several properties of the HIV-1 Envs that could limit their
ability to elicit bnAbs. These include protection of the conserved
structures by variable loops (1–3), remarkable genetic diversity
(4), a glycan shield (5), steric occlusion (6), and conformational
masking (7). Until 6 years ago, only a handful of bnAbs, including
b12, 2G12, 2F5, and 4E10, were known. Although the structural
and functional studies of those bnAbs revealed some important
neutralization epitopes (8), such bnAbs have not been successfully
elicited by any vaccination approach.
In 2007, we first noted that in HIV-1 specific bnAbs the num-
ber of amino acid mutations from their closest corresponding
germline sequences was significantly higher than that of bnAbs
against the SARS CoV coronavirus, and Hendra and Nipah viruses,
which cause self-limiting acute infections (9). Using a large non-
immune IgM library, we identified several HIV-1 Env specific
antibodies and found that they had fewer somatic mutations than
the HIV-1 bnAbs, as well as limited neutralizing activity (9). These
findings indicated that elicitation of HIV-1 bnAbs would require
far more extensive maturation processes than those needed to gen-
erate the bnAbs against the SARS CoV and henipaviruses. So, we
have suggested that the difficulty of eliciting these bnAbs may be
due, at least in part, to the complex and prolonged maturation
pathways required for the development of bnAbs against the HIV-
1, which can take long time (10). We thus speculated that this
may represent another significant challenge in the development of
effective HIV-1 vaccines.
We quantified the number of mutations in human monoclonal
antibodies (mAbs) that we selected from phage libraries generated
from an HIV-1-infected patient with a known time of infection
(10). We calculated the number of amino acid mutations per heavy
chain V gene, and defined it as antibody somatic mutational diver-
sification (ASMD). We compared the extent and dynamics of the
ASMD between HIV-1-specific mAbs and a panel of SARS CoV-
specific mAbs. Our experiments based on the ASMD predicted that
elicitation of HIV-1-specific bnAbs would take at least 3 years. An
illustrative mathematical model using the ASMD rate based on
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an exponential time dependent function suggested that a much
longer time would be needed for the required maturation, unless
somatic diversification had already been initiated from an inter-
mediate antibody. Thus, all these initial studies corroborated our
hypothesis that the infrequent occurrence or absence of bnAbs
in HIV-1-infected patients could be due, at least in part, to the
lack or limited availability of B cell receptors that rapidly mature
into bnAbs. Therefore, we suggested that appropriate immuniza-
tion protocols of long duration need to be developed using the
knowledge gained from the exploration of antibody maturation
pathways in humans (10).
From the striking observation that all known potent HIV-1
bnAbs are highly divergent from their putative germline prede-
cessors in contrast to bnAbs against henipaviruses and SARS CoV
coronavirus, we hypothesized that, since the germline antibod-
ies are so different compared to the highly somatically mutated
HIV-1 bnAbs, they may not bind to the Env. This led us to
the hypothesis that the immunogenicity of the highly conserved
epitopes on the HIV-1 native envelope glycoproteins (Envs) is
reduced or eliminated by their very weak or absent interactions
with germline antibodies, which could not initiate and/or sus-
tain immune responses leading to elicitation of bnAbs: even if
immune responses are initiated and sustained, the maturation
pathways are so complex that help and long times may be needed
for their elicitation. To test our antibody germline/maturation
hypothesis, we designed germline-like antibodies corresponding
to the known bnAbs b12, 2G12, 2F5, X5, m44, and m46 (the
latter three antibodies were discovered in our laboratory and pos-
sess HIV-1 cross-reactivity with moderate neutralizing activities)
and evaluated them for binding to Envs (11). We found that
while germline-like X5, m44, and m46 bound to Envs with rel-
atively high affinity, the germline-like precursors of b12, 2G12,
and 2F5 failed to bind Envs in an ELISA assay although their
corresponding mature bnAbs bound strongly. These results pro-
vided initial evidence that the Env structures containing conserved
epitopes might not initiate humoral responses due to limited
or absent binding to the germline precursors of bnAbs. These
germline precursors may also be of limited availability as recently
reported (12).
Following that initial study, we expanded our investigation
to different variants of the two different antibodies (b12 and
X5) including their closest germline counterparts and several
germline-like intermediates (13). The experiments showed that
b12 intermediate antibodies neutralized only some HIV-1 iso-
lates with relatively weak potency. In contrast, intermediates of
X5 neutralized a subset of the tested HIV-1 isolates with efficien-
cies comparable to those of the matured X5. These results helped
explain the relatively high immunogenicity of the coreceptor bind-
ing site on gp120 and the abundance of CD4-induced (CD4i)
antibodies in HIV-1-infected patients (X5 is a CD4i antibody) as
well as the maturation pathway of X5. In the case of b12, germline-
like intermediates along the maturation pathway were shown to
not only bind some Envs but also human self antigens, suggesting
that antigens other than the Envs could help guide the immune
system through the b12 maturation pathway.
Therefore, we proposed a conceptually new vaccination
approach, in which it is critical to identify primary immunogens
that bind to the germline antibodies that are predecessors
of bnAbs. If needed, these immunogens should be combined
with secondary immunogens that recognize intermediate and/or
matured antibodies to guide the immune system through the pro-
longed, complex maturation pathways (14). In this respect, we
envisioned that the knowledge of human antibodyomes would
become indispensable to elucidate the origin, diversity, and mat-
uration pathways of bnAbs and discover germline-like intermedi-
ates of bnAbs that could provide a basis for the design of novel
HIV-1 vaccine immunogens (14, 15).
In recent years, several groups have reported a number of new
bnAbs that were identified from multiple HIV-1 infected individ-
uals using designed novel antigen baits and advanced technolo-
gies implemented in isolating human mAbs and high-throughput
sequencing (16). Particularly, Haynes, Kwong, Stamatatos, Scheif
et al. have dealt with a large amount of data delineating struc-
tural, genetic determinants, and maturation pathways of different
bnAbs. These studies not only confirmed our previous findings
that the Envs fail to engage germline versions of bnAbs but also
suggested possible holes in B cell repertoires and demonstrated
the implications of our antibody germline/maturation hypothe-
sis for finding germline-like precursors, intermediates as well as
for designing immunogens that could potentially bind to such
bnAb intermediates. In this report, we discuss the recent advance-
ments in HIV-1 vaccine research in the context of the antibody
germline/maturation hypothesis, and highlight critical factors to
be considered when exploring germline-like precursors and inter-
mediates of bnAbs. We also report for the first time using 454
sequencing data analysis of a human cord blood IgM library
to identify putative germline precursors of the heavy and light
chains of VRC01-like antibodies. These naturally occurring cord
blood-derived VRC01-like heavy and light chains may be useful
as putative templates for designing novel vaccine immunogens
that can lead to the elicitation of VRC01-like antibodies and for
understanding the maturation pathways of this bnAb. Still there
are major challenges to be overcome. New empirical and semi-
empirical approaches could be successful; recently, new paradigms
were discussed that could better fit our increased knowledge of
HIV immunopathology and which could possibly be more help-
ful in guiding future vaccine research than did past unsuccessful
approaches (17).
MATERIALS AND METHODS
ANTIBODYOME DATABASE AND TOOLS
DNA isolation, amplification, and 454 sequencing of the human
cord blood IgM library were previously described in detail (18,
19). For quality control, we trimmed the 454 sequence reads and
retained only sequences with lengths of more than 300 nucleotides,
covering the entire antibody variable domains consisting of all
three complementarity determining regions (CDRs) along with
framework regions (FRs). We used IMGT/HighV-QUEST for
immunogenetic and statistical analyses (20). The output results
from the IMGT/HighV-QUEST analysis were stored in a local
PostgreSQL database, and structured query language (SQL) was
used to retrieve the data for further analysis. Statistical calculations
were carried out using JMP10® statistical software (SAS Institute,
Cary, NC, USA).
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COMPUTATIONAL ANALYSIS OF ANTIBODY SEQUENCES
Antibody sequences from IGHV1-2 and IGK3-11 lineages were
retrieved from our local antibodyome database consisting of
immunogenetic data derived from 454 sequencing of the human
cord blood IgM library using SQL statements. Amino acid
sequence identities between each of the selected lineage sequences
from the 454 sequence data and pertinent germline sequences were
calculated based on the pairwise alignment using local BLAST
as implemented in BioEdit v7.0.9 (21). Phylogenetic analysis was
carried out using the Archaeopteryx software (22).
RESULTS AND DISCUSSION
EXPLORING THE ANTIBODY GERMLINE/MATURATION HYPOTHESIS
Our earlier observation of the extensive maturation of HIV-1
bnAbs in contrast to those against some viruses causing acute
infections led to the antibody germline/maturation hypothesis (9–
11, 13, 14). According to this hypothesis, it is critical to identify
immunogens that would bind to germline and/or intermediate
antibodies of bnAbs, as well as the exploration of antibodyomes
could be useful for identifying such immunogens (14). Figure 1
describes the timeline involving some of the key developments in
current HIV-1 vaccine research focused on antibody germline-like
intermediates and maturation pathways of bnAbs. Major research
efforts in this direction were spearheaded by deep sequencing and
structural biology studies of VRC01-like and other CD4-binding
site (CD4b) antibodies from HIV-1-infected individuals. These
studies delineated possible maturation pathways of such antibod-
ies with high levels of somatic mutations and convergence in anti-
body recognition (23, 24). Both studies revealed that the putative
germline precursors of these antibodies had weak or no appar-
ent affinity for Env, and acquisition of a large number of somatic
mutations were needed for the breadth and potency of these anti-
bodies. These studies also explored antibody diversity and found
many intermediates of similar lineages of the heavy chain genes
from the two IGHV families VH1-2 and VH1-46 that paired with
different light chain genes. Thus, analysis of the VRC01-related
antibodyome from HIV-1 infected patients revealed B cell matura-
tion pathways that may help guide the vaccine-induced elicitation
of such antibodies. However, if we could find germline-like inter-
mediates of such bnAbs from a naïve antibody repertoire, then
FIGURE 1 |Timeline of the antibody germline/maturation hypothesis and experiments.
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potential vaccine immunogens developed based on those tem-
plates would stimulate an adequate B cell immune response in
healthy humans. To this end, we identified VRC01-like intermedi-
ate antibodies from a naïve antibody library of human cord blood,
which is presented later in the text.
We previously analyzed the IgM repertoires of healthy individ-
uals and identified several intermediates of b12 from the VH1-3
gene family (15). Sequence analysis of 28,925 unique sequences
from the IgM repertoires revealed a CDRH3 with a length (20
amino acids) and sequence similar (50%) to that of the b12
CDRH3, but the V gene associated with that CDRH3 was found to
be HV4-b (15). This finding indicates that long CDRH3s may not
be a limiting factor for the development of bnAbs (25) although
long CDRH3 motifs with certain amino acid preferences and/or
associations with particular heavy or light chain families favoring
polyreactivity may not be undermined.
Stamatatos and coworkers have conducted experiments screen-
ing a large panel of recombinant Envs for binding to the germline
predecessors of b12, NIH45-46, and 3BNC60 to test how Env
immunogens interact with the predicted germline versions of
known bnAbs (26). They found that the mature bnAbs reacted
with diverse Envs but the corresponding germline antibodies did
not. They examined in detail the germline b12 and its chimeric
forms – either the germline heavy chain paired with the mature
light chain and vice versa – to test whether they could interact
with any of the recombinant Envs derived from clade A, B, and C
viruses. Among all the recombinant Envs tested, at least one Env
(QH0692) was found to bind a b12 chimera with a mature heavy
chain. However, this chimera failed to mediate calcium mobiliza-
tion, indicating no BCR activation via BCR-antigen engagement.
In other studies, they found that the elimination of certain con-
served glycosylation sites on Envs led to the binding of germline
versions of VRC01 and NIH45-46 and BCR activation (27) but
that the modified Envs did not interact with PG9 and 447-52D
germlines (28).
Haynes and coworkers have succeeded in finding Envs capa-
ble of engaging the germline versions of a CD4bs bnAb, CH103,
while studying the co-evolution of the antibody in an HIV-1
infected patient (29). They found that CH103 is less mutated
than most other CD4bs bnAbs, and importantly that the unmu-
tated common ancestor of the CH103 lineage avidly bound the
transmitted/founder HIV-1 Envs. This finding suggests that early
founder Envs could bind optimally to the germline and inter-
mediate versions of CH103, and therefore, are promising vaccine
immunogens, representing an important step forward in HIV-1
vaccine development.
Similarly, the maturation pathway of the potent V1V2-directed
HIV-neutralizing antibody, CAP256–VRC26, has been described,
in which a germline-like intermediate with a 35-amino acid residue
long CDRH3 was shown to bind and neutralize the superinfecting
virus weakly, but did not bind or neutralize heterologous viruses
(30). These results suggest that the CAP256–VRC26 lineage could
be initiated by using a rare superinfecting-virus-like V1V2 Env.
In another successful effort in identifying an Env that could
engage the germline versions of bnAbs, Scheif and coworkers
devised a computation-guided approach combined with in vitro
screening to engineer a gp120 outer domain. The designed protein
not only bound to multiple VRC01-class bnAbs and their germline
precursors but also activated B cells expressing diverse intermedi-
ates of the bnAbs (31). Therefore, priming with the protein and
subsequent boosting with more native immunogens could help
induce early somatic mutations and the ultimate elicitation of
VRC01-class bnAbs.
Interestingly, Nussenzweig and coworkers’ study showed that
somatic mutations of the FRs and insertions of some bnAbs are
required for their broad and potent HIV-1 neutralizing activ-
ity (32). Based on structural information, they made different
germline versions of VRC01, NIH45–46, 12A21, and 3BNC117,
and found that mutations in FRs were also essential for binding,
breadth, and potency of most bnAbs. This suggested that certain
framework mutations could be critical and should be preserved for
designing the intermediates of such bnAbs. Several other studies
mining the HIV-1 infected donors’antibodyomes (33–35) revealed
putative intermediates of bnAbs. Many of them with lower levels
of somatic hyper mutations could bind to selective Envs; for exam-
ple, intermediates of PGT121-134 were able to preferentially bind
native Envs relative to monomeric gp120 (36). We also identified
2F5-like antibodies (m66 and m66.6) with much fewer mutations
than 2F5 and suggested their use as a model system for elicitation
of such antibodies (37, 38).
All these newly discovered bnAbs raise the hopes for effective
HIV-1 vaccine development as they reveal characteristic features
of bnAbs that could help us understand the immunological basis
critical for their production and also serve as templates for ratio-
nal vaccine design. Therefore, the focus has been dramatically
shifted to explore and overcome the immunological hurdles asso-
ciated with the elicitation of bnAbs, namely, extensive somatic
mutations of bnAbs. Major challenges remain in identification of
intermediates with a minimal number of mutations, and appro-
priate Env immunogens that would bind such intermediates and
activate BCRs, which can lead to the maturation of the interme-
diate antibodies to bnAbs. Recently, new paradigms that better fit
our increased knowledge of HIV immunopathology and which
may be more helpful in guiding future vaccine research than did
past unsuccessful approaches were discussed (17).
IDENTIFICATION OF PUTATIVE GERMLINE-LIKE INTERMEDIATES IN THE
MATURATION PATHWAYS OF VRC01
We previously characterized the human cord blood cell-derived
IgM antibodies using 454 sequencing to study gene diversity and
somatic mutations (19). Naïve germline antibody repertoires, par-
ticularly from babies, may be quite unique for understanding the
B cell maturation pathways, as they can also mount an immune
response against HIV-1 as recently found (39). Our earlier gene
usage analysis of the cord blood IgM repertoire showed the biased
IGHV gene usages (19) as similar to adult IgM repertoires (40).
However, we already noted that the IGHV1-2 gene usage was sig-
nificantly higher in the cord blood IgM repertoire, i.e., an overall
contribution of 20% as compared to 8% in adult IgM repertoires.
This suggested that the cord blood IgM repertoire may be advan-
tageous for the exploration of the IGHV1-2*02 lineages when
studying germline precursors and intermediates of VRC01 heavy
chain. A total of 5,624 heavy chain and 1,096 light chain sequences
of IGHV1-2 and IGKV3-11 lineages, respectively, were used to
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FIGURE 2 | Phylogram and sequence alignment of selected (A) heavy
and (B) light chain sequences found in human cord blood IgM libraries
of IGHV1-2 and IGKV3-11 lineages, respectively. Phylogenetic trees
constructed using the amino acid sequences of top 10 putative germline-like
precursors as found in the cord blood library along with mature heavy and
light chains of VRC01 are shown. Multiple sequence alignments of heavy
and light chain sequences along with their corresponding germline
sequences, V1-2*02 and KV3-11*01, made using BLOSUM62 scoring
matrices, conserved substitution (blue) and non-conserved substitution
(white) are shown.
select the top 10 sequences as closest intermediates for VRC01 in
each heavy and light chain categories by using local BLAST search-
ing. We performed phylogenetic analysis of the selected sequences
to identify genetic relationships among VRC01-like intermediates
of heavy (Figure 2A) and light (Figure 2B) chains. We found two
of the antibody heavy chains, HWAV6 and JHEDT, which were
100% identical to the IGHV1-2*02 germline sequence. Remark-
ably, their CDRH3 sequences had the same length (14 amino
acids) as that of the VRC01 heavy chain. For these 10 heavy chain
sequences, the CDRH3 lengths ranged from 8 to 16 amino acids
with sequence variations at the junctions. One of the germline
sequences, JHEDT, had a point mutation at Cys100Tyr (Kabat
numbering) of CDRH3 that exactly mimicked the residue Tyr100
of CDRH3 in VRC01. The residue Tyr100 at CDRH3 of VRC01
is most likely contributed by the IGHD3-16*02 germline with a
point mutation Cys100Tyr. The other heavy chain sequence I76AT,
which was the closest to VRC01 heavy chain, also had the same
mutation at Cys100Tyr. One of the other germline sequences,
HWAV6, had Trp100B (Kabat numbering) of CDRH3 that exactly
mimicked the residue Trp100B of CDRH3 in VRC01. Intriguingly,
the Trp100B residue is a junctional amino acid of the CDRH3 in
germline HWAV6, and it exactly replicates the Trp100B junctional
residue of CDRH3 in VRC01. This suggests a possible maturation
mechanism involved in the VRC01-like intermediates where junc-
tional amino acids could determine the maturation pathway far
preceding the somatic hypermutation required for affinity matu-
ration (41). Most of the closest IGHV genes, 8 out of 10 shown
in the Figure 2A, have at least one mutation in the V region, and
www.frontiersin.org August 2014 | Volume 5 | Article 398 | 5
Prabakaran et al. HIV-1 bnAbs: germline/maturation hypothesis
two sequences, G2W0T and GD60C, have two mutations at each
of the CDRH1. The pre-existing amino acid mutations found in
the V region and CDRH3 sequence information may inform the
design of heavy chain germline-like precursors and intermediates,
and help naturally reconstruct the B cell clonal lineages in the
maturation pathways of VRC01.
Light chain recognition of Envs by VRC01 and VRC01-related
antibodies has been studied in detail using structural and 454
sequencing data (33). The VRC01 light chain commonly uses the
IGKV1-33 lineage and has a characteristic five amino acid long
CDRL3 and a distinctive two amino acid deletion in CDR L1.
Therefore, we selected the IGKV1-33 lineage sequences with five
amino acid length CDRL3s, but no sequences were found with a
two amino acid deletion in CDR L1 (Figure 2B). All of them had
either framework or CDR mutations or both. Four of them had a
point mutation at CDRL1 and seven of them had a point mutation
at CDRL3.
The structural basis for germline gene usage of VRC01-related
antibodies targeting the CD4bs has been previously described (42),
which revealed a set of signature features for these antibodies that
were verified by mutagenesis. These signature features explained
the origin of the IGVH1-2 gene and antibody resistance for some
Env sequences. We found that characteristic residues including
the Trp100B of heavy chains were conserved while light chains did
not have any characteristic residues as reported previously (42).
However, other pre-existing amino acid mutations in light chains
could have implications for the VRC01-related intermediates with
a characteristic CDRL3 of five amino acid length.
DISTRIBUTIONS OF CDR LENGTHS AND AMINO ACIDS IN THE
VRC01-RELATED GERMLINE GENES
We analyzed the amino acid length distributions of CDRH3 and
CDRL3 sequences that were of VRC01 origins, namely, IGHV1-2
and IGKV3-11 for heavy and light chains, respectively, as derived
from the human cord blood IgM library (Figure 3). The CDRH3
lengths ranged from 4 to 27 amino acids, indicating high CDR3
length diversity (Figure 3A). VRC01 has a CDRH3 length of 14
amino acids, which is shorter than those of most other anti-HIV-1
antibodies (25). The LCDR3 lengths ranged from 4 to 14 amino
acids (Figure 3B). The CDRL3 of VRC01 has a characteristic length
of five amino acids with a mature genetic signature (33). Analysis
of the human cord blood IgM repertoire showed only a fraction
of such light chains with a shorter length of five amino acids
(Figure 3B). Frequency distributions of amino acid compositions
of CDRH1 and CDRH2 in IGHV1-2 sequences as observed in
the human cord blood IgM repertoire are plotted in Figures 3C,D,
FIGURE 3 | Distributions of amino acid length in (A) CDRH3, (B) CDRL3 and amino acid compositions in (C) CDRH1 and (D) CDRH2 as derived using
the gene families of IGHV1-2 and IGKV3-11 in human cord blood IgM library showing the CDR3 lengths diversity and pre-existing mutations at
CDRH1 and H2.
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respectively. These plots show that there are position specific varia-
tions in the CDRH1 and CDRH2 regions of IGHV1-2 genes. These
could indicate possible IGHV1-2 specific pre-existing amino acid
mutations in CDRH1 and CDRH2, as observed in several naïve
antibody heavy chain sequences, which could inform the design of
germline precursors and intermediates of VRC01-like antibodies.
V–D–J RECOMBINATION DIVERSITY AND IGHD READING FRAME
USAGES IN THE VRC01-RELATED GERMLINE GENES
We previously observed that the V–D–J rearrangement patterns
occurred at different frequencies with 1,430 V–D–J combinations
in a human cord blood IgM repertoire (19). Figure 4A shows the
V–D–J diversity associated with IGHV1-2 gene sequences using
a bubble plot for comparison with different D and J genes. The
VRC01 heavy chain uses IGHD3-16 and IGHJ2 genes to recombine
with IGHV1-2. However, other VRC01-related antibodies exhibit
a skewed usage of IGHJ genes although at least three different IGHJ
genes (IGHJ1, IGHJ2, and IGHJ4) are involved (23). As the human
cord blood IgM library has a large functional V–D–J diversity, it
can be used to identify potential VRC01-like heavy chain germline
precursors and intermediates.
In jawed vertebrates the expressed heavy chains may use any of
the six IGHD reading frames (RFs); however, RF1 is thought to be
the preferred one as it mostly encodes tyrosine and glycine. The
remaining five RFs encode either hydrophobic or charged amino
acids, but the use of inverted RF1, RF2, and RF3 are discour-
aged. Preferential usage of IGHD RFs has been long implicated
in B cell development and antigen-specific antibody production
(43–45), and selected based upon its amino acid content (46).
Genetic control of IGDH RF preference over the regulation of
repertoire development has been recognized (47). Here, we have
analyzed the productive IGHD RF usages in a human cord blood
IgM library. Frequency distribution of RFs is plotted using a pie
chart as depicted in Figure 4B. We noted that there were not any
highly restricted usages of the IGHD RFs although some preferen-
tial usages depending on the IGHD genes were found. This clearly
indicates that IGHD RFs diversity could add more diverse amino
acid contents leading to enormous CDRH3 diversity. It may also be
possible that intermediates with different RF choices play a critical
role in selecting certain maturation pathways efficiently.
CONCLUSION
The antibody germline/maturation hypothesis led to a paradigm
shift in the design of immunogens for bnAb elicitation, as well as
the realization of the importance of the complexity of the bnAb
maturation pathways, and exploration of human antibodyomes
(14). In fact, human antibodyome exploration is also promising
for other fields of science and medicine (14, 48). This antibody-
ome approach is now a major direction of research in the HIV-1
vaccine field (16, 49). An important goal is to precisely identify
naturally occurring germline-like precursors and intermediates of
bnAbs that could help designing novel immunogens, which could
activate the corresponding BCRs and drive the immune system to
produce bnAbs within a short period of time. We presented an
approach using a human cord blood IgM library to identify puta-
tive germline precursors and intermediates of VRC01-like heavy
and light chains, which could be useful in reconstructing the B
cell clonal lineages in the maturation pathways of VRC01-related
bnAbs. This method has the potential to help in the identification
of naturally occurring germline-like precursors and intermediates
of any known bnAb and in the development immunogens based
on HIV-1 Envs (50) and peptides (51), as well as non-HIV-1 mole-
cules (12). However, major challenges remain and new paradigms
that better fit our increased knowledge of HIV immunopathology
could possibly be more helpful in guiding future vaccine research
than did past unsuccessful approaches (17).
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